Edison Oncology Holding ^{Filed Terms, NYSE American: EOHC}

We are a clinical-stage biopharmaceutical company focused on developing innovative small-molecule therapies for cancer by unlocking the potential of existing drugs and compounds. We seek to make meaningful improvements through strategic reformulation and / or repurposing using a modernized understanding of their mechanisms of action to address significant unmet medical needs. Our development strategy prioritizes product candidates that may qualify for accelerated marketing approval under the U.S. Food and Drug Administration’s (FDA) expedited approval pathway for serious conditions (21 CFR Part 314, Subpart H). This approach enables us to pursue initial marketing approval for pharmaceutical agents based on surrogate or intermediate clinical endpoints and, potentially, earlier than we would otherwise be able to. Although our strategy is to seek out accelerated approval for any applicable product candidate, none of our current clinical trials should be considered registration studies for accelerated approval. If any of our product candidates receive accelerated approval, we will need to conduct post-approval studies to confirm the product’s clinical benefit. Notwithstanding, the accelerated approval pathway does not increase the probability of our product candidates achieving regulatory or clinical success.